Clarify Medical announced that the United States Patent and Trademark Office has issued US patent 9,901,747, entitled “Phototherapy Light Engine.” The patent covers a precision, targeted phototherapy device using UVB LEDs, reflectors, window filter and thermal management system to optimize therapeutic power and uniformity of narrowband UVB light treatment.
The Clarify System’s patented light engine has significant advantages compared to conventional fluorescent bulbs. Proprietary LED technology and an optical window filter emits light with a higher percentage of therapeutic energy – filtering out non-therapeutic wavelengths which cause skin burning. And, unlike conventional bulbs, the Clarify light engine provides uniform output at the treatment head – ensuring that patients receive the correct dose on the entire treatment area. Additional safety features, including a light shield and proximity safety switch, help to ensure that light therapy is only delivered to the intended treatment area, protecting healthy skin from unnecessary exposure.
“This is the first home phototherapy system available in the United States that uses UVB LED technology to treat chronic skin conditions,” said Rex Bright, Interim President and CEO of Clarify Medical. “We’re excited to introduce this innovative technology to improve precision and control over home phototherapy, which we believe will improve outcomes for patients.”
The Clarify System received FDA clearance in May 2017 with indications for the treatment of vitiligo, psoriasis, eczema, seborrheic dermatitis and leucoderma on all skin types (I-VI).
